Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Identifieur interne : 007915 ( PubMed/Checkpoint ); précédent : 007914; suivant : 007916Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Auteurs : T. Ito [Japon] ; M. Suno [Japon] ; K. Sakamoto [Japon] ; Y. Yoshizaki [Japon] ; K. Yamamoto [Japon] ; R. Nakanishi [Japon] ; Y. Hirano [Japon] ; M. Irie [Japon] ; T. Kurosaki [Japon] ; S. Otani [Japon] ; M. Yamane [Japon] ; S. Sugimoto [Japon] ; K. Miyoshi [Japon] ; T. Oto [Japon]Source :
- Transplantation proceedings [ 1873-2623 ]
Descripteurs français
- KwdFr :
- Abdomen (anatomopathologie), Acide mycophénolique (analogues et dérivés), Acide mycophénolique (usage thérapeutique), Adulte, Femelle, Humains, Immunosuppresseurs (usage thérapeutique), Immunosuppression thérapeutique (), Lymphangioléiomyomatose (), Lymphangioléiomyomatose (anatomopathologie), Lymphangioléiomyomatose (traitement médicamenteux), Lymphoedème (traitement médicamenteux), Lymphoedème (étiologie), Maladie résiduelle, Pelvis (anatomopathologie), Prednisolone (usage thérapeutique), Qualité de vie, Sirolimus (usage thérapeutique), Tacrolimus (usage thérapeutique), Transplantation pulmonaire, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- analogues et dérivés : Acide mycophénolique.
- anatomopathologie : Abdomen, Lymphangioléiomyomatose, Pelvis, Tumeurs du poumon.
- traitement médicamenteux : Lymphangioléiomyomatose, Lymphoedème, Tumeurs du poumon.
- usage thérapeutique : Acide mycophénolique, Immunosuppresseurs, Prednisolone, Sirolimus, Tacrolimus.
- étiologie : Lymphoedème.
- Adulte, Femelle, Humains, Immunosuppression thérapeutique, Lymphangioléiomyomatose, Maladie résiduelle, Qualité de vie, Transplantation pulmonaire.
English descriptors
- KwdEn :
- Abdomen (pathology), Adult, Female, Humans, Immunosuppression (methods), Immunosuppressive Agents (therapeutic use), Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Lung Transplantation, Lymphangioleiomyomatosis (drug therapy), Lymphangioleiomyomatosis (pathology), Lymphangioleiomyomatosis (surgery), Lymphedema (drug therapy), Lymphedema (etiology), Mycophenolic Acid (analogs & derivatives), Mycophenolic Acid (therapeutic use), Neoplasm, Residual, Pelvis (pathology), Prednisolone (therapeutic use), Quality of Life, Sirolimus (therapeutic use), Tacrolimus (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Mycophenolic Acid.
- chemical , therapeutic use : Immunosuppressive Agents, Mycophenolic Acid, Prednisolone, Sirolimus, Tacrolimus.
- drug therapy : Lung Neoplasms, Lymphangioleiomyomatosis, Lymphedema.
- etiology : Lymphedema.
- methods : Immunosuppression.
- pathology : Abdomen, Lung Neoplasms, Lymphangioleiomyomatosis, Pelvis.
- surgery : Lymphangioleiomyomatosis.
- Adult, Female, Humans, Lung Transplantation, Neoplasm, Residual, Quality of Life.
Abstract
Sirolimus (SRL) is used to treat pulmonary lymphangioleiomyomatosis (P-LAM). There is limited evidence that SRL has systemic efficacy for the patients with extrapulmonary lymphangioleiomyomatosis (E-LAM) remaining after lung transplantation (LT) for P-LAM. This report examines the efficacy of SRL treatment for the patient with E-LAM remaining after an LT for P-LAM.
DOI: 10.1016/j.transproceed.2015.12.021
PubMed: 26915883
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26915883Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.</title><author><name sortKey="Ito, T" sort="Ito, T" uniqKey="Ito T" first="T" last="Ito">T. Ito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Suno, M" sort="Suno, M" uniqKey="Suno M" first="M" last="Suno">M. Suno</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan. Electronic address: sunoma@pharm.okayama-u.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Sakamoto, K" sort="Sakamoto, K" uniqKey="Sakamoto K" first="K" last="Sakamoto">K. Sakamoto</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Yoshizaki, Y" sort="Yoshizaki, Y" uniqKey="Yoshizaki Y" first="Y" last="Yoshizaki">Y. Yoshizaki</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Yamamoto, K" sort="Yamamoto, K" uniqKey="Yamamoto K" first="K" last="Yamamoto">K. Yamamoto</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Nakanishi, R" sort="Nakanishi, R" uniqKey="Nakanishi R" first="R" last="Nakanishi">R. Nakanishi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Hirano, Y" sort="Hirano, Y" uniqKey="Hirano Y" first="Y" last="Hirano">Y. Hirano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Irie, M" sort="Irie, M" uniqKey="Irie M" first="M" last="Irie">M. Irie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Kurosaki, T" sort="Kurosaki, T" uniqKey="Kurosaki T" first="T" last="Kurosaki">T. Kurosaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Otani, S" sort="Otani, S" uniqKey="Otani S" first="S" last="Otani">S. Otani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamane, M" sort="Yamane, M" uniqKey="Yamane M" first="M" last="Yamane">M. Yamane</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Sugimoto, S" sort="Sugimoto, S" uniqKey="Sugimoto S" first="S" last="Sugimoto">S. Sugimoto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Miyoshi, K" sort="Miyoshi, K" uniqKey="Miyoshi K" first="K" last="Miyoshi">K. Miyoshi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Oto, T" sort="Oto, T" uniqKey="Oto T" first="T" last="Oto">T. Oto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:26915883</idno><idno type="pmid">26915883</idno><idno type="doi">10.1016/j.transproceed.2015.12.021</idno><idno type="wicri:Area/PubMed/Corpus">000985</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000985</idno><idno type="wicri:Area/PubMed/Curation">000985</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000985</idno><idno type="wicri:Area/PubMed/Checkpoint">000985</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000985</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.</title><author><name sortKey="Ito, T" sort="Ito, T" uniqKey="Ito T" first="T" last="Ito">T. Ito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Suno, M" sort="Suno, M" uniqKey="Suno M" first="M" last="Suno">M. Suno</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan. Electronic address: sunoma@pharm.okayama-u.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Sakamoto, K" sort="Sakamoto, K" uniqKey="Sakamoto K" first="K" last="Sakamoto">K. Sakamoto</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Yoshizaki, Y" sort="Yoshizaki, Y" uniqKey="Yoshizaki Y" first="Y" last="Yoshizaki">Y. Yoshizaki</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Yamamoto, K" sort="Yamamoto, K" uniqKey="Yamamoto K" first="K" last="Yamamoto">K. Yamamoto</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Nakanishi, R" sort="Nakanishi, R" uniqKey="Nakanishi R" first="R" last="Nakanishi">R. Nakanishi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</wicri:regionArea><wicri:noRegion>Okayama University</wicri:noRegion></affiliation></author><author><name sortKey="Hirano, Y" sort="Hirano, Y" uniqKey="Hirano Y" first="Y" last="Hirano">Y. Hirano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Irie, M" sort="Irie, M" uniqKey="Irie M" first="M" last="Irie">M. Irie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Kurosaki, T" sort="Kurosaki, T" uniqKey="Kurosaki T" first="T" last="Kurosaki">T. Kurosaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Otani, S" sort="Otani, S" uniqKey="Otani S" first="S" last="Otani">S. Otani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamane, M" sort="Yamane, M" uniqKey="Yamane M" first="M" last="Yamane">M. Yamane</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Sugimoto, S" sort="Sugimoto, S" uniqKey="Sugimoto S" first="S" last="Sugimoto">S. Sugimoto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Miyoshi, K" sort="Miyoshi, K" uniqKey="Miyoshi K" first="K" last="Miyoshi">K. Miyoshi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Oto, T" sort="Oto, T" uniqKey="Oto T" first="T" last="Oto">T. Oto</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Thoracic Surgery, Okayama University Hospital, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></analytic><series><title level="j">Transplantation proceedings</title><idno type="eISSN">1873-2623</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdomen (pathology)</term><term>Adult</term><term>Female</term><term>Humans</term><term>Immunosuppression (methods)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (pathology)</term><term>Lung Transplantation</term><term>Lymphangioleiomyomatosis (drug therapy)</term><term>Lymphangioleiomyomatosis (pathology)</term><term>Lymphangioleiomyomatosis (surgery)</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Mycophenolic Acid (analogs & derivatives)</term><term>Mycophenolic Acid (therapeutic use)</term><term>Neoplasm, Residual</term><term>Pelvis (pathology)</term><term>Prednisolone (therapeutic use)</term><term>Quality of Life</term><term>Sirolimus (therapeutic use)</term><term>Tacrolimus (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abdomen (anatomopathologie)</term><term>Acide mycophénolique (analogues et dérivés)</term><term>Acide mycophénolique (usage thérapeutique)</term><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Immunosuppression thérapeutique ()</term><term>Lymphangioléiomyomatose ()</term><term>Lymphangioléiomyomatose (anatomopathologie)</term><term>Lymphangioléiomyomatose (traitement médicamenteux)</term><term>Lymphoedème (traitement médicamenteux)</term><term>Lymphoedème (étiologie)</term><term>Maladie résiduelle</term><term>Pelvis (anatomopathologie)</term><term>Prednisolone (usage thérapeutique)</term><term>Qualité de vie</term><term>Sirolimus (usage thérapeutique)</term><term>Tacrolimus (usage thérapeutique)</term><term>Transplantation pulmonaire</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mycophenolic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term><term>Mycophenolic Acid</term><term>Prednisolone</term><term>Sirolimus</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide mycophénolique</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Abdomen</term><term>Lymphangioléiomyomatose</term><term>Pelvis</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term><term>Lymphangioleiomyomatosis</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunosuppression</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Abdomen</term><term>Lung Neoplasms</term><term>Lymphangioleiomyomatosis</term><term>Pelvis</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Lymphangioleiomyomatosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangioléiomyomatose</term><term>Lymphoedème</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide mycophénolique</term><term>Immunosuppresseurs</term><term>Prednisolone</term><term>Sirolimus</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Lung Transplantation</term><term>Neoplasm, Residual</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Immunosuppression thérapeutique</term><term>Lymphangioléiomyomatose</term><term>Maladie résiduelle</term><term>Qualité de vie</term><term>Transplantation pulmonaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sirolimus (SRL) is used to treat pulmonary lymphangioleiomyomatosis (P-LAM). There is limited evidence that SRL has systemic efficacy for the patients with extrapulmonary lymphangioleiomyomatosis (E-LAM) remaining after lung transplantation (LT) for P-LAM. This report examines the efficacy of SRL treatment for the patient with E-LAM remaining after an LT for P-LAM.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26915883</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>26</Day></DateCreated><DateCompleted><Year>2016</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2623</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Transplantation proceedings</Title><ISOAbbreviation>Transplant. Proc.</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.</ArticleTitle><Pagination><MedlinePgn>271-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transproceed.2015.12.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0041-1345(15)01208-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Sirolimus (SRL) is used to treat pulmonary lymphangioleiomyomatosis (P-LAM). There is limited evidence that SRL has systemic efficacy for the patients with extrapulmonary lymphangioleiomyomatosis (E-LAM) remaining after lung transplantation (LT) for P-LAM. This report examines the efficacy of SRL treatment for the patient with E-LAM remaining after an LT for P-LAM.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">The course of the patient's recovery from an LT for P-LAM was complicated by lymphedema in the left femoral region that was caused by two E-LAM lesions remaining in the left pelvic cavity and in the retroperitoneal area. After the LT was performed, the patient started SRL treatment to reduce the E-LAM lesions. The daily SRL dose, selected based on the standard SRL dose for P-LAM, was initiated at 1 mg/d and was maintained at 2 mg/d. The remaining E-LAM lesions and lymphedema in the left femoral region improved in approximately 9 months after the LT with the administration of both SRL and the standard immunosuppressive therapy used by Okayama University Hospital, including tacrolimus, mycophenolate mofetil, and prednisolone. The SRL and tacrolimus trough concentrations in whole blood were maintained within the therapeutic window for the next 1.5 years after initiation of SRL treatment. The patient experienced no severe adverse events that required discontinuation of the SRL treatment during this time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The patients with remaining E-LAM lesions may receive SRL treatment to improve the quality of life after LT for P-LAM as effective therapy in cases where the patient's recovery is complicated by E-LAM lesions.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suno</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan. Electronic address: sunoma@pharm.okayama-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshizaki</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Oncology Pharmaceutical Care & Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirano</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irie</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosaki</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otani</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamane</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oto</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Proc</MedlineTA><NlmUniqueID>0243532</NlmUniqueID><ISSNLinking>0041-1345</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="N">Abdomen</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016040" MajorTopicYN="Y">Lung Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018192" MajorTopicYN="N">Lymphangioleiomyomatosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="N">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26915883</ArticleId><ArticleId IdType="pii">S0041-1345(15)01208-7</ArticleId><ArticleId IdType="doi">10.1016/j.transproceed.2015.12.021</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Ito, T" sort="Ito, T" uniqKey="Ito T" first="T" last="Ito">T. Ito</name></noRegion><name sortKey="Hirano, Y" sort="Hirano, Y" uniqKey="Hirano Y" first="Y" last="Hirano">Y. Hirano</name><name sortKey="Irie, M" sort="Irie, M" uniqKey="Irie M" first="M" last="Irie">M. Irie</name><name sortKey="Kurosaki, T" sort="Kurosaki, T" uniqKey="Kurosaki T" first="T" last="Kurosaki">T. Kurosaki</name><name sortKey="Miyoshi, K" sort="Miyoshi, K" uniqKey="Miyoshi K" first="K" last="Miyoshi">K. Miyoshi</name><name sortKey="Nakanishi, R" sort="Nakanishi, R" uniqKey="Nakanishi R" first="R" last="Nakanishi">R. Nakanishi</name><name sortKey="Otani, S" sort="Otani, S" uniqKey="Otani S" first="S" last="Otani">S. Otani</name><name sortKey="Oto, T" sort="Oto, T" uniqKey="Oto T" first="T" last="Oto">T. Oto</name><name sortKey="Sakamoto, K" sort="Sakamoto, K" uniqKey="Sakamoto K" first="K" last="Sakamoto">K. Sakamoto</name><name sortKey="Sugimoto, S" sort="Sugimoto, S" uniqKey="Sugimoto S" first="S" last="Sugimoto">S. Sugimoto</name><name sortKey="Suno, M" sort="Suno, M" uniqKey="Suno M" first="M" last="Suno">M. Suno</name><name sortKey="Yamamoto, K" sort="Yamamoto, K" uniqKey="Yamamoto K" first="K" last="Yamamoto">K. Yamamoto</name><name sortKey="Yamane, M" sort="Yamane, M" uniqKey="Yamane M" first="M" last="Yamane">M. Yamane</name><name sortKey="Yoshizaki, Y" sort="Yoshizaki, Y" uniqKey="Yoshizaki Y" first="Y" last="Yoshizaki">Y. Yoshizaki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 007915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26915883
|texte= Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26915883" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |